Novonesis has reached an agreement to acquire DSM-Firmenich’s share of the Feed Enzyme Alliance for EUR 1.5 billion. The deal involves Novonesis taking over the sales and distribution activities of the feed enzyme business, marking the dissolution of the long-standing alliance formed over 25 years ago.
The acquisition follows DSM-Firmenich’s decision to separate its Animal Nutrition & Health business unit, which includes the feed enzyme division. The transaction, which will be completed in 2024, covers approximately EUR 300 million in annual net sales.
Under the deal, Novonesis, the combined company of Novozymes and Chr. Hansen, will integrate DSM-Firmenich’s sales and distribution operations into its existing product innovation and production capabilities. The move is expected to strengthen Novonesis’ ability to serve both current and new customers, with enhanced insights into key markets and products.
DSM-Firmenich will receive approximately EUR 1.4 billion net after transaction costs and taxes. The company has also confirmed its commitment to fully separating its Animal Nutrition & Health business by 2025 and will seek transaction options for its exit from the sector.
Novonesis CEO Ester Baiget stated that the acquisition positions the company to meet growing global demand for sustainable animal feed solutions, addressing challenges like land and water scarcity. DSM-Firmenich CEO Dimitri de Vreeze expressed confidence that the business would continue to thrive under Novonesis’ leadership.


































-scaled.jpg)














